TAI~LE I Cytotoxicity Generated between Cells from HLA-A, -B, -C-Identical Donors
CTL were generated as previously described (9) . Briefly, 9 × 10 s responding cells were cultured for 10 d with 3 × 106 2,000-rad-irradiated stimulator cells in a 25-cm 2 tissue culture flask. To generate secondary effectors primary cultures were harvested after 10 d and either cryopreserved or restimulated immediately. 3 X 10 s primed cells (fresh or thawed after cryopreservation) were restimulated with 9 X l0 s 2,000-rad-irradiated stimulator cells in 8 ml culture medium supplemented with 1.5 ml heat-inactivated human plasma, and harvested after 4d.
Cytotoxicity was determined in a standard 4-h 5XCr-release assay (8) using 1 x 104 phytohemagglutinin (PHA)-stimulated target cells and effector to target cell ratios of 40:1, 15:1, and 4:1. CML assays were performed in triplicate and percent specific lysis was calculated as [(mean counts per minute, experimental -mean counts per minute, media)/(mean counts per minute, detergent -mean counts per minute, media)] X 100.
Results and Discussion
Detection of a CML Target Antigen by a Unique Responder]Stimulator Combination. As part of a systematic analysis of histocompatibility antigens that differ between 12 donors completely matched for the serologically defined HLA-A, -B, and -C antigens, mixed lymphocyte cultures (MLC) were generated between many combinations of these donors, restimulated in secondary MLC, and the lymphocytes tested for CTL activity with target cells from the donor used as stimulator. CTL FC4/FR4, directed against HLA-A1 and -BS, was used as control to show comparable lysability of the different target cells (Table I) . Strong eytotoxieity (>20% lysis) on PHA-stimulated lymphoblasts was seen in only one combination: donor H9 anti-donor W7. Detection of this antigen by CML seemed to require secondary restimulation, because little cytotoxicity was seen after primary stimulation (data not shown). To maximize reproducibility in subsequent studies of the specificity of this cytotoxic activity, large batches of primed cells were frozen after primary stimulation, and were used as Family Studies Indicate Control by Gene(s) Independent of HLA. The pattern of lysis observed in the population was consistent with at least three possible specificities of the CTL: (a) for a molecular variation in the B7 molecule that is not yet serologically defined; (b) for the product of an allele of another HLA-linked gene in strong positive linkage disequilibrium with the HLA-B7 allele; or (c) for a human 'minor' histocompatibility antigen recognized in conjunction with an HLA antigen highly associated with B7. Studies of three generations of family B (Table II) prove that the antigen recognized by H9/W7 is controlled by at least one gene distinct from B7. The donors in the family whose cells express the cytotoxic target antigen are those that have inherited the 'a' haplotype, which encodes HLA-B 7. However, one of the six members (FB12) who has inherited this haplotype does not express the antigen recognized by the CTL H9/W7; since the typing indicates clearly that FB12 inherited the B7 haplotype from his mother FB4, failure of his cells to express the CTL antigen must indicate that the B7 gene per se is not sufficient for expression of the CTL antigen. Furthermore, these data make hypothesis b unlikely; there has been no recombination on the B7 haplotype between HLA-Aw24 and DR4, so the postulated HLA-B7- (Table II) . In this family, both parents are positive for B7, but only the father expresses the antigen recognized by H9/W7. If the target antigen were related only to expression of a particular structurally distinct subset of the B7 molecule, then only the children who inherited the B7 from the father ought to express the antigen recognized by H9/W7. Instead, all children, including one who inherited B7 from the mother and not from the father (FW5), express the antigen. A plausible interpretation of this data is that although the mother expressed an appropriate B7, she lacked the relevant allele of the minor antigen; FW5 expresses the full antigenic complex since he inherited the B7 gene from his mother and the minor antigen from his father. There is an alternate explanation: that the CTL antigen that is recognized on the father's cells is encoded by genes on both his HLA-B7 and -B18 haplotypes; however, it is statistically improbable (P ~1/40) that his A30-B 18 haplotype should encode the antigen when most B7-negative haplotypes in the population do not. Data from these two families suggest that there is another gene, provisionally designated HM 1 for human minor 1, that controls the expression of the complete antigen. This antigen is not identical to the H-Y antigen because it is expressed on cells of female donors as well. The phenotype frequency for HM1, calculated from the phenotype frequency among HLA-B7-positive donors (17/35) ( Fig. 1) , is ~50%, which implies a gene frequency of ~30%, if the gene is expressed codominantly.
Evidence for Possible In Vivo Priming During Pregnancy.
The combination H9/W7 is unusual in its ability to recognize HM 1. As can be seen from Table I , four other combinations of HMl-negative cells against HM 1-positive cells, e.g., B 17/F2 or K2/ W7, do not detect HM1. Furthermore, other potential minor antigen differences are not recognized strongly in any of the 14 other combinations of HLA-matched donors. The lower level of lysis (<20%), seen in many combinations, is consistent with Iaspecific kill on the PHA-stimulated targets (10) . Is the detection of a minor histocompatibility antigen by the CTL response H9 anti-W7 really due to an unusual responsiveness of H9 or perhaps due to a uniqueness of cells from donor W7? Two additional data argue for the former. First, W7 did not stimulate cells from other donors against minor histocompatibility antigens (Table I) . Second, although H9/ W7 preferentially recognized only one antigen, the relative differences within the group of HLA-B7-negative donors suggest further complexity (Fig. 1) . Indeed, another donor was identified, whose cells stimulated cells from H9 against at least two other minor histocompatibility antigens (manuscript in preparation). Thus, H9 is unique in the ability of her cells to recognize multiple minor histocompatibility antigens.
Studies of minor histocompatibility antigens in mice indicate that detection of these antigens normally requires both an initial in vivo priming and H-2 identity between responder and stimulator during priming. We therefore investigated whether an in vivo priming of donor H9 could account for the donor's unusual reaction against minor histocompatibility antigens. As H9 never received any blood transfusions or organ transplants, pregnancy would have been the only known allogeneic exposure. It has already been demonstrated, by detection of Y chromosome-containing lymphocytes in the blood of mothers with male fetuses, that an exchange of small amounts of white cells can occur (11) . Theoretically it is likely that these cells are removed from the maternal circulation quite rapidly by humoral and cellular responses against antigens controlled by the paternal HLA haplotype of the fetal cells. Studies of available members of H9's family revealed the postulated conditions for an in vivo priming against minor histoeompatibility antigens (Table I) . Both children are HLA-A, -B, -C, and -DR identical with their mother. One child (FH3) is SB different and expresses the HM1 target antigen. The other child is SB identical with her mother and does not express HM 1. These data not only prove that one of the children carries the relevant antigen necessary for a priming during pregnancy but also show a virtual HLA identity between mother and children, which may have provided optimal conditions for priming against minor histocompatibility antigens during pregnancy. No other unusual features of H9's pregnancies could be identified.
Although minor histocompatibility antigens are thought to play an important role in transplantation biology, our knowledge about these antigens in humans is very limited. Cells from donors like the one described in this study, i.e., in whom a priming against minor histocompatibility antigens has occurred, will facilitate identification of "immunodominant" minor histocompatibility antigens and investigation of the biological role of these antigens.
Summary
A normal female donor (Hg) is described, whose cells generate strong cytotoxicity against a human minor histocompatibility antigen in vitro. These cytotoxic T lymphocytes are generated after secondary restimulation with cells from an HLA-A, -B, -(2, and -DR-matched donor and are HLA restricted (HLA-BT). No other donor could be identified whose cells responded to this antigen. The two children of donor H9 are virtually HLA identical to her and one of the children expresses the relevant minor histocompatibility antigen. These data suggest that priming in vivo during pregnancy has facilitated cytotoxic T cell response to human minor histocompatibility antigens in vitro.
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